;

This content has been developed by Galderma and is intended for Healthcare Professionals Only

Prescribing information for Alluzience - UK (Botulinum toxin type A) is available by clicking this link.
Prescribing information for Alluzience - Ireland (Botulinum toxin type A) is available by clicking this link.

An innovative formulation designed to be liquid from inception to injection1. Ready-to-use and no need to reconstitute, Alluzience (Botulinum toxin type A) is engineered for precision and performance.1,2
Alluzience is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between eyebrows) seen at a maximum frown in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.1

Innovation

Designed to be liquid from inception to injection1

No human or animal-derived exipients1

Could help to reduce preparation time and treatment waste1,3

Improved patients’ psychological well-being on the SmPC1

Performance

Rapid onset of effect, seen as early as 24 hours1,2

Long duration up to 6 months1,2

No reconstitution required, ready-to-use1

Precise dosing for replicable results over multiple treatment cycles1,2

* The exact time point in the first 24 hours was not captured.
ABO, botulinum toxin type-A; ILA, Investigator’s Live Assessment.

 

Proven treatment satisfaction in 85% of patients at 1 month1,3* [Note 1]

[85% (n=250), vs Placebo, 9% (n=122) p<0.0001]

 

Clinically proven uplift to psychological
well-being1,3,5

Alluzience provides significant improvements in patient happiness and confidence based on the FACE-Q3© scales1
[Week 1 to month 3: p<0.001 vs placebo, months 4 and
5: p<0.01 vs placebo and month 6: p<0.05 vs placebo.
Alluzience (n=250), Placebo (n=122)]

A majority of adverse reactions re.ported with Alluzience in clinical trials were of mild to moderate intensity and reversible.1
The most frequently reported adverse reactions were headache and injection site reactions.1
The incidence of adverse reactions tended to decrease with repeated treatments.1

Contraindications include hypersensitivity to the active substance or to any of the excipients, presence of infection at the proposed injection sites and presence of myasthenia gravis, Easton Lambert syndrome or amyotrophic lateral sclerosis.1

For full information on contraindications, adverse events and precautions, please refer to the Summary of Product Characteristics before use.

Shop Now

** Compound approved for therapeutic use in December 1990 and aesthetic use in April 2009.

References: 1. Alluzience Summary of Product Characteristics; 2. Hilton S, et al. Dermatol Surg. 2022;48(11):1198-202; 3. Gerber PA, et al. Poster presented at IMCAS World Congress. January 2023. Paris, France. 4. Galderma Data on File MA-52573; 5.  Kassir R et al. Dermatol Ther (Heidelb) 2013;3(2):179–189; 6.  Maas C et al. Aesthet Surg J 2012;32(1 Suppl):S8–S29; 7.  Monheit GD et al. Dermatol Surg 2020;46(1):61–69; 8. Moy R et al. Arch Facial Plast Surg 2009;11(2):77–83; 9. Warren H et al. Plast Surg Nurs 2020;40(1):37–44; 10. Brandt F et al. Dermatol Surg 2009;35(12):1893–1901; 11(2):77–83. 11. Rzany B et al. Dermatol Surg 2007;33(1 Spec No):S18–S25; 12. Gubanova E et al. Aesthet Plast Surg 2018;42(6):1672–1680; 13. Azzalure Summary of Product Characteristics; 14.  Molina B et al. J Eur Acad Dermatol Venereol 2015;29(7):1382–1388; 15. Schlessinger J et al. Dermatol Surg 2021;47:504–509.

Prescribing information for Alluzience - UK (Botulinum toxin type A) is available by clicking this link.
Prescribing information for Alluzience - Ireland (Botulinum toxin type A) is available by clicking this link.

 

 

UKI-ALZ-2600009 Date of Production March 2026

 

Adverse events should be reported. For the UK, Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website:
www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd,
Email: medinfo.uk@galderma.com Tel: +44 (0) 300 3035674